Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics

Claudia Steiner1, Stéphanie Arnould2, Augustin Scalbert1 and Claudine Manach1*

1INRA, UMR 1019, Unité Nutrition Humaine, Centre Clermont-Theix, F-63122 St Genès Champangelle, France
2Laboratoire d’Oncologie Moléculaire, UMR 484 INSERM-UdA, Centre Jean Perrin, F-63011 Clermont-Ferrand, France

Epidemiological evidence together with preclinical data from animal and in vitro studies strongly support a correlation between soy isoflavone consumption and protection towards breast and prostate cancers. The biological processes mediated by isoflavones, and especially by genistein, have been extensively studied, yet without leading to a clear understanding of the cellular and molecular mechanisms of action involved. This review discusses the existing gaps in our knowledge and evaluates the potential of the new nutrigenomic approaches to improve the study of the molecular effects of isoflavones. Several issues need to be taken into account for the proper interpretation of the results already published for isoflavones. Too often knowledge on isoflavone bioavailability is not taken into account; supra-physiological doses are frequently used. Characterization of the individual variability as defined by the gut microflora composition and gene polymorphisms may also help to explain the discrepancies observed so far in the clinical studies. Finally, the complex inter-relations existing between tissues and cell types as well as cross-talks between metabolic and signalling pathways have been insufficiently considered. By appraising critically the abundant literature with these considerations in mind, the mechanisms of action that are the more likely to play a role in the preventive effects of isoflavones towards breast and prostate cancers are reviewed. Furthermore, the new perspectives opened by the use of genetic, transcriptomic, proteomic and metabolomic approaches are highlighted.

Isoflavones: prostate cancer: breast cancer: chemoprevention: nutrigenomics

Isoflavones are a class of bioactive phytochemicals that have been widely studied for their potential role in the prevention of various chronic diseases, such as cardiovascular diseases, neurodegenerative diseases, osteoporosis, cancers… Soy and its processed products (tofu, tempeh, miso, natto, soymilk, soy-based yogurts and desserts) are the only sources providing high quantities of isoflavones in the human diet. Isoflavone intake has been estimated to 25–50 mg/day in Asian countries, with a maximum around 100 mg/d for elderly Japanese men(1). Americans and Europeans, who have low soy content in their habitual diet, only consume few milligrams of isoflavones per day. However, advertising on the beneficial effects of isoflavones, especially for relieving postmenopausal symptoms, has led to self-supplementation through isoflavone-rich foods or dietary supplements. Isoflavones in soybeans mainly include daidzein, genistein and glycitein, which are present in glycosylated or aglycone forms (Fig. 1). The structural similarity of aglycones with 17β-estradiol gives them the capacity to bind estrogen receptors (ERs) and to induce hormone-like effects. Isoflavones and their protective role against various pathologies involving hormonal dysregulation have been extensively studied because of this particular property.

The current evidence provided by preclinical studies on the role of isoflavones in reducing prostate and breast cancer risk has been recently reviewed(2–4). A summary of the main data available will be made here, to highlight the present limitations in our understanding of their mechanisms of action, and to evaluate the potential of nutrigenomic approaches to further clarify these mechanisms.

Human studies

The lower risk of prostate and breast cancer in areas of high soy and isoflavone intake, especially in Asia(5), as well as the increased risk observed for Asian people who migrated to Western countries or adopted a westernised lifestyle(6–8).

Abbreviations:
- AF, activation functions; AP-1, activator protein 1; AR, androgen receptor; CDK, cyclin-dependent kinase; COMT, catechol-O-methyltransferase; CYP, cytochrome P450 monooxygenase; Da, daidzein; DHEA, dihydroepiandrosterone; DHT, dihydrotestosterone; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; Eq, equol; ER, estrogen receptor; ERE, estrogen responsive elements; ERK, extracellular signal-regulated kinase 1; FSH, follicle-stimulating hormone; Ge, genistein; GPs, glutathione peroxidase; GSR, glutathione reductase; GST, glutathione S-transferase; GTP-CH 1, GTP cyclohydrolase 1; IGF-1, insulin-like growth factor 1; IGF-1R, insulin-like growth factor 1 receptor; IGFBP, insulin-like growth factor binding protein; JNK, c-jun N-terminal kinase; LDL, low density lipoprotein; LH, luteinising hormone; MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinase; MS, mass spectrometry; MT-1X, metallothionein 1X; mGST, microsomal glutathione S-transferase; NF-κB, nuclear factor-kappa B; NMR, nuclear magnetic resonance; PI3K, phosphatidylinositol-3 kinase; PIN, prostatic intra-epithelial neoplasia; PPAR, peroxisome proliferator-activated receptor; PR, progesterone receptor; PSA, prostate specific antigen; QR, quinone reductase; SD rats, Sprague–Dawley rats; SHBG, sex hormone binding globulin; SNP, single nucleotide polymorphisms; SOD, superoxide dismutase; TEBS, terminal end buds; TGF-β, transforming growth factor β; TIMP, tissue inhibitor of metalloproteinase; TRAMP, transgenic adenocarcinoma of the mouse prostate; UDPGT, UDP-glucuronosyl-transferase; VEGFR, vascular endothelial growth factor receptor.

*Corresponding author: C. Manach, fax +33 473 62 46 38, email manach@clermont.inra.fr
are well known. A recent meta-analysis compiling 2 cohort studies and 6 case–control studies in Western and Asian populations estimated that high soy food intake can be related to a 30% reduction in prostate cancer risk (odds ratio 0.70, 95% CI 0.59–0.83)\(^{(9)}\). For breast cancer, a smaller risk reduction (odds ratio 0.86, 95% CI 0.75–0.99), stronger for premenopausal women, was found in a meta-analysis compiling 6 cohort and 12 case–control studies\(^{(10)}\). Asian women whose soy intake was high during puberty experienced lower risk for breast cancer than women who did not consume soy products or did only as adults\(^{(11,12)}\).

Among hundreds of dietary components that have been proposed as potential cancer preventive agents, only a few have been used in clinical trials. The impact of isoflavone supplementation has been studied on some prostate cancer-related endpoints such as serum levels of Prostate-Specific Antigen (PSA), PSA velocity, plasma levels of testosterone, dihydrotestosterone (DHT), insulin-like growth factor 1 (IGF-1) and IGF binding protein 3 (IGFBP-3). Among the 11 trials recently reviewed by Messina et al.\(^{(13)}\), only 4 reported a significant effect on PSA levels. However, reduction in prostate cancer risk may occur without any reduction in PSA levels. No beneficial effects were observed on levels of steroids, or on IGF-1/IGFBP-3 ratio. One study which compared the incidence of apoptosis in prostate tumours of patients supplemented or not with red clover isoflavones (160 mg/d for 7–54 days), reported significantly higher apoptosis in supplemented patients than in control subjects (1:48% vs. 0.25%, \(P=0.0007\)), specifically in regions of low to moderate-grade cancer (Gleason grade 1–3)\(^{(14)}\). It is worth noting that no adverse effects were observed in any trial. The whole available data have been considered sufficiently encouraging to justify the funding of additional Phase II trials by the NIH\(^{(13)}\).

Messina et al.\(^{(15)}\) recently discussed the published and ongoing clinical breast cancer studies. Three double-blind randomized controlled trials reported no effect of a 1 to 2-year isoflavone supplementation on mammographic density used as a marker of breast cancer risk\(^{(16–18)}\). A 2-week administration of a soy supplement (45 mg/d isoflavones) increased epithelial cell proliferation and progesterone receptor (PR) expression in normal breast tissue, suggesting an estrogen agonist effect\(^{(19)}\). However, the potential link with proliferation of breast cancer cells is difficult to assess. Conflicting results have been obtained regarding the impact of soy isoflavones on hormone-related breast cancer risk factors such as plasma steroid hormone levels, Sex Hormone Binding Globulin (SHBG) plasma levels, urinary 2:16α-hydroxyestrone ratio, and menstrual cycle length\(^{(20)}\).

The inconsistencies in the results and the failure to observe clear clinical effects may be explained, at least in part, by disparities in experimental designs, in the form of isoflavone administration, the dose, or the duration of the study. Furthermore, diverse subpopulations may respond differently to isoflavone consumption due to age, sex, ethnic background, gene polymorphisms, history of cancer, known risk factors, nutritional status, hormonal status or colonic microbiota composition. In this regard, the most critical parameters affecting the biological responses to isoflavone intake remain to be identified. The populations or subpopulations which may benefit, or possibly may experience some adverse effects while consuming isoflavones, also need to be identified.

The factors likely to affect isoflavone bioavailability may first modulate physiological responses to isoflavone intake. A compilation of 15 bioavailability studies in humans showed that plasma metabolite concentrations usually reach about 2 μmol/l after consumption of 50 mg isoflavones (aglycone equivalent)\(^{(21)}\). Inter-individual variability in isoflavone absorption and metabolism has never been assessed in large and ethnically non-homogeneous populations, however some bioavailability studies suggest that it may be high. Maximum plasma concentrations ranged between 4 and 27 μmol/l genistein among 20 American men with prostate cancer challenged with a high pharmacological dose of genistein\(^{(22)}\). Furthermore, a recent clinical study showed that genistein and daidzein bioavailability, evaluated by plasma pharmacokinetics, was significantly lower in Caucasian than in Asian men after single or 10-day isoflavone supplementation\(^{(23)}\). It would therefore be extremely useful to accurately measure the real individual exposure to isoflavones rather than only the isoflavone intake in clinical studies.

The intestinal microflora also plays a crucial role in the metabolism of isoflavones. Various bacterial metabolites are known to be produced, among which some may exert biological activities\(^{(24–26)}\). Equol is the most studied metabolite since it has been shown to be more estrogenic than its precursor daidzein in many in vitro studies and in animal models\(^{(27)}\). There is great inter-individual variability in the capacity to produce equol, and only 30–50% of the Western population exhibits the ‘equol-producer’ phenotype\(^{(28)}\). Song et al. recently reported that the equol-producer phenotype was more frequent in Korean American than in Caucasian American women (51% vs. 36%) living in the same area of the US\(^{(29)}\). Several studies suggested that equol-producers may gain more benefits from soy consumption than non-equol-producers. In a case–control study in Japanese and Korean men, the proportion of equol-producers was 1.5- to 2-fold higher in the control group than in the group of men with prostate cancer\(^{(30)}\). More favourable hormonal profiles (lower plasma concentrations of estrone, estrone-sulfate, testosterone, androstenedione, dehydroepiandrosterone (DHEA), DHEA-sulfate, and midluteal progesterone) and higher concentrations of SHBG were also found in equol-producing premenopausal women compared to non-equol-producers, which was consistent with a lower risk for breast cancer\(^{(31)}\). Frankenberg et al. did not find such hormonal
differences in postmenopausal women, but equol-producing women had higher 2:16α-hydroxyestrone ratio, which has also been related to a lower breast cancer risk(32). Similar results were obtained in breast cancer survivors(33). Mammographic density was 39% lower in equol-producing postmenopausal women compared with non-producers, which is again consistent with a lower breast cancer risk in equol-producers(34). Niculescu et al. studied the effects of a high-dose isoflavone supplementation (900 mg/d for 84 days) on gene expression changes in lymphocytes of 30 postmenopausal women. Using microarray analysis they showed that isoflavone treatment in equol-producer subjects differentially affects gene expression as compared with non-producers, with a stronger effect on some estrogen-responsive genes in equol-producers(35). It is not yet clear whether equol itself is the active metabolite responsible for these beneficial effects, or whether it is only a biomarker for a particular microbial community composition able to elicit favourable metabolisms in addition to equol production. Some fingerprinting methods, such as terminal restriction fragment length polymorphism (TRFLP) analysis, are now available to compare the overall patterns of gut microbial composition between individuals(36). These high-throughput methods should enlighten the role of specific bacteria and help to adequately stratify individuals in future human intervention and observational population-based studies.

Metabolomics is another high-throughput method that may be useful to deal with inter-individual variability. Nuclear magnetic resonance (NMR) and mass spectrometry (MS) techniques allow the simultaneous detection of hundreds or thousands of compounds present in human plasma, urine or tissues(37). Multivariate statistical analyses of the datasets obtained for groups of individuals that differ for one controlled criterion, such as isoflavone intake, microflora composition or type of cancer, provide a list of variables discriminating the groups. The identification of these discriminating variables may lead to the discovery of novel biomarkers for the particular criterion studied. Metabolic profiling using these biomarkers could then be used in clinical or cohort studies to better assess individual exposure to isoflavones, as well as to stratify individuals on the basis of their metabolic capacities or other phenotypes.

Another new possibility, offered by nutrigenetics, is the access to valuable information on individual genotypes through sequencing of targeted single nucleotide polymorphisms (SNPs)(38). As some polymorphisms in genes coding for membrane transporters, protein carriers or metabolic enzymes such as glucuronosyl-transferases could affect the nature and concentrations of isoflavone metabolites present in target tissues, it may be useful to search for correlations between individual genotypes, isoflavone bioavailability and isoflavone effects. However, the relevant SNPs that would be related to the responsiveness to isoflavone consumption are not identified to date. Beyond the gene polymorphisms that may affect bioavailability, two recent studies demonstrated the major interest of considering the inter-individual variability in the genetic background of a population to evaluate the isoflavone biological effects. Hedelin et al. studied the interactions between dietary phytoestrogen intake, ERβ polymorphisms, and the risk of prostate cancer in a case–control study performed in 2096 Swedish men(39). For one particular SNP of the ERβ gene, a higher phytoestrogen and isoflavone consumption was associated to a significantly reduced prostate cancer risk (respectively 57% and 27%) in subjects who were homozygous or heterozygous for the variant allele, whereas no association could be found in subjects who were homozygous for the wild-type allele (58% of the population). In another cohort of 1988 menopausal women from UK, isoflavone exposure was positively associated with SHBG levels only in the fraction of the population that carried the Asn variant of the SHBG D356N polymorphism, which is associated with a reduced SHBG clearance(40). As higher SHBG levels have been associated with a lower breast cancer risk, isoflavone consumption may be particularly beneficial to these women. It is worth noticing that the authors would have concluded that isoflavone exposure was not associated to SHBG levels if they had considered the population as a whole, without stratification according to the genotype. Gene-isoflavone interactions may partly explain some of the discrepancies observed in the first clinical studies conducted so far, especially if the allele frequencies differed between the populations considered. Nevertheless, high statistical powered studies will be required in order to take the relevant gene polymorphisms into account in the investigation of isoflavone effects.

Another element that may explain the inconsistencies observed in clinical studies is the relevance of the endpoint biomarkers used. Biomarkers for staging and monitoring the evolution of prostate and breast cancer development are critically needed to evaluate the impact of any therapeutic intervention. Considering that cancers are multi-factorial and variable diseases, it appears today unrealistic to rely on a single biomarker (such as PSA for prostate cancer) to assess diagnosis, prognosis, and prediction of response to therapy. Complex combinations of markers coming from transcriptomic, proteomic as well as metabolomic approaches are certainly more appropriate and promising perspectives can already be seen. Rhodes et al. have analysed gene expression profiles in 40 published cancer microarray data sets, comprising 38 million gene expression measurements from >3700 cancer samples(41). This study generated a set of 69 genes that were commonly dysregulated in 12 types of cancers including prostate and breast cancers. Proteomic data have also been used on a blinded cohort to identify patients with prostate cancer with a high specificity(41–43). There is now a great hope that these high-throughput methods will lead to the discovery of early biomarkers for preclinical metabolic dysregulations associated with the first stages of carcinogenesis. Many novel important genes involved in prostate carcinogenesis, such as Hepsin or Alpha-methylacyl-CoA racemase (AMACR), have been identified by using microarray analysis(44). NMR-based metabolomic analyses to target biomarkers for prostate cancer are under development(45). Novel early biomarkers will improve our understanding of the initial stages of the diseases and will be essential to study the preventive effects of dietary intervention such as isoflavone supplementation.

Therefore, nutrigenomic approaches should allow to better assess individual metabolism and to better evaluate the effects of isoflavones at the individual level and at early stages of the diseases.
Animal studies

As demonstrated above, human studies are still hampered with major weaknesses, and more controllable animal and cellular models are very useful to investigate isoflavone effects. Different animal models of prostate cancer such as Lobund-Wistar rats (spontaneous tumours), rats treated with various type of carcinogens [N-methyl-N-nitrosourea (NMU), 7,12-dimethylbenz(a)anthracene (DMBA), 2-amino-1-methyl-6-phenylimidazopyridine (PhIP)] or implants of testosterone propionate, transgenic mice (TRAMP), xenograft models (e.g. immunodeficient mice implanted with human tumour cell lines) have been used to explore the effects of isoflavones on prostate cancers. In more than 40 such studies, isoflavones were shown to reduce both the incidence and the size of prostate tumours.[2,3,46]

Isoflavones may act at different stages of carcinogenesis, by inhibiting the appearance of prostatic intra-epithelial neoplasia (PIN) or their progression into carcinomas, but the determination of their timing of action requires further experiments.

Much more conflicting results have been obtained in animal models of breast cancer, as isoflavones have been shown to inhibit as well as to promote the growth of mammary tumours, depending on the studies. Many parameters may explain such discrepancies including the various nature of the animal models used, the test compounds, the dose and the mode of administration, or the timing of isoflavone exposure. Overall, isoflavones were mainly shown to prevent or to delay chemically-induced mammary carcinogenesis in prepubertal or pre-menopausal adult female rats. The protective effects of isoflavones at the prepubertal period have been linked to a promotion of early mammary gland differentiation, leading to a decreased number of immature terminal end buds (TEBs), sites for malignant transformation, and an increased number of more differentiated lobules.[47–51]. Complex cross-talks between steroids, growth factors and other pathways are involved in the differentiation process. Hilakivi-Clarke et al. reported that the pro-differentiating effect of isoflavones was associated with a repression of ERα and PR expression but an increase of ERβ expression in mammary glands.[52]. Lamartiniere et al. suggested that isoflavone exposure in the prepubertal period mainly promotes mammary epithelial differentiation through the transient activation of epidermal growth factor (EGF) signalling pathway.[53].

The most frequent types of breast cancer are the estrogen-dependent breast tumours in postmenopausal women. Widely used animal models for these types of tumours are immunodeficient mice implanted with estrogen-dependent human breast cancer MCF-7 cells, combined with ovariectomy and in some cases with estradiol implants releasing high doses of estradiol that stimulate the growth of MCF-7 implanted cells. The group of Hellfich published several consistent studies showing that genistein at nutritionally relevant doses (0.025–0.1 % in the diet) stimulates tumour growth or negates the inhibitory effect of tamoxifen in such xenograft models.[53–56]. In such models the circulating levels of endogenous estrogens are either much lower (ovariectomy) or much higher (estradiol implants) than the physiological levels observed in postmenopausal women. Hence the relevance of the xenograft models to evaluate the effects of weak estrogenic compounds, the activity of which may depend on the levels of endogenous estrogens, has been criticised. Recently, Ju et al. developed a mouse model with slow-growing estrogen-dependent tumours in ovariectomised athymic mice, using silastic implants to deliver estradiol at levels similar to those observed in postmenopausal women.[57]. Again, genistein administered in the diet at 500 ppm was shown to act in an additive manner with the low levels of circulating estradiol and stimulated the growth of the tumorigenic MCF-7 cells in this model.

Several authors reported that in utero exposure to high-dose isoflavones (s.c. injections) increased the susceptibility of rats to chemically-induced mammary cancers later in life, in the same way as in utero exposure to high levels of endogenous estrogens.[49,58]. This effect has been related to an increased number of TEBs, and a reduction in epithelial differentiation in the mammary gland. However, other authors reported that a more nutritional exposure to soy protein isolate (but not to genistein alone) in utero through maternal diet protected young adult rats from NMU-induced mammary tumourigenesis.[59]. Early exposure to isoflavones or at least to genistein before puberty may cause transient and persistent effects on mammary gland development, as well as on hormone receptor levels.[60]. These imprinting-like effects may thus differ depending on dose and timing of exposure and lead to adverse or beneficial effects in later life.

Dolinoy et al. provided the first evidence that early in utero exposure to genistein can produce permanent epigenetic changes.[61]. They showed that maternal dietary genistein supplementation (250 ppm) of mice during gestation shifted the coat colour of heterozygous viable yellow agouti (A⁻/a) offspring towards pseudoagouti and decreased the incidence of obesity during adulthood. These marked phenotypic changes were mediated by an increased methylation of six CpG sites located in a retrotransposon upstream of the Agouti gene which determines coat colour. An exciting hypothesis of research has been put forward with this study. DNA methylation is known to control cellular differentiation in the mammary epithelium. Thus, epigenetic events associated with in utero or prepubertal exposure to genistein may also contribute to the effects observed on animal mammary gland differentiation.[62]. Such imprinting phenomena are extremely difficult to study in humans. Extrapolation of data from animal models must take into account some differences in isoflavone bioavailability in rodents and in humans. For example, all laboratory animals have been shown to be constitutive equol-producers, and equol is the major circulating metabolite in animals while it is only present in a low proportion in humans.[7].

Animal studies also showed that isoflavones exert various effects depending on their structures and application forms. The large majority of studies have been conducted with genistein. When used alone, daidzein was shown to be equivalent to genistein at the same dose (250 ppm in the diet) in delaying mammary tumour development in MMTV-neu mice.[63]. In contrast, prepubertal exposure of Sprague–Dawley female rats to 250 ppm daidzein in the diet neither enhanced mammary gland differentiation nor suppressed DMBA-induced mammary tumour development as previously demonstrated for genistein.[64]. Furthermore, dietary daidzein only had a slight stimulatory effect on MCF-7 tumour growth in athymic mice, whereas (±)-equol did not stimulate tumour growth.[65]. Thus, the effects observed with genistein should not be extrapolated...
to other isoflavones, and the various isoflavones may affect different metabolic or signalling pathways. Moreover, consumption of genistein in pure or highly enriched forms (as in soy protein isolates) has a greater stimulatory effect on MCF-7 cells implanted in immunodeficient mice than the same content of dietary genistein in less purified soy flour. Other authors reported a higher beneficial effect of soymilk or soy protein isolate toward chemically-induced cancer as compared to pure genistein. Soybeans contain a wide variety of other phytochemicals such as saponins, protease inhibitors like the Bowman-Birk inhibitor, phenolic acids, phytic acid, and lignans that may exert additional or synergistic effects with isoflavones. Taking supplements may thus have different effects than increasing soy food consumption.

Cell models

Isoflavones have been shown to inhibit proliferation and/or induce apoptosis in various androgen-dependent or androgen-independent prostate cancer cell lines. The concentrations used were generally high, allowing cytotoxic effects, but anti-proliferative effects have also been observed at lower concentrations (5 μM) of genistein. Again, the impact of genistein is more complex in breast cancer cell lines than in prostate cell lines, since genistein stimulates cell growth of estrogen-dependent cells when used at concentrations lower than 10 μM but inhibits their growth at higher concentrations. High concentrations of genistein also inhibit the growth of ER-negative cell lines such as MDA-MB-231, indicating that this isoflavone can exert cellular effects independently from ER.

One major limit of such in vitro studies is that they use isoflavone concentrations far exceeding the concentrations commonly achieved in human plasma or tissues after soy consumption. The available data indicate that concentrations as high as 1–2.5 nmol/g of each isoflavone may be achieved in human prostate or prostatic fluid after short-term supplementation with high nutritional doses of isoflavones and that in Asian men basal levels of total isoflavones are about 0.4 nmol/g in prostate. Isoflavone concentrations in human plasma or tissues after soy consumption are far exceeding the concentrations commonly achieved in human plasma or tissues after soy consumption. The available data indicate that concentrations as high as 1–2.5 nmol/g of each isoflavone may be achieved in human prostate or prostatic fluid after short-term supplementation with high nutritional doses of isoflavones.

Mechanisms of action

Although many studies have been conducted to understand the effects of soy isoflavones on breast and prostate cancer, available data are inconsistent and the mechanisms of action are still not entirely elucidated. Studies on animal and cellular models have firmly established that isoflavones are active compounds, showing quite variable effects depending on the dose, the form of administration, or the timing and duration of exposure. Serious concerns were raised about a possible estrogen-like detrimental effect of genistein through growth stimulation of pre-existing estrogen-sensitive mammary tumours. In the present state of our knowledge, the increasing isoflavone self-supplementation should be considered with caution until the mechanisms of action of isoflavones are better understood.

As questioned in the titles of S. Barnes, “Isoflavones = phytooestrogens and what else?”, or M. McCarty “Isoflavones made simple — Genistein’s agonist activity for the beta-type estrogen receptor mediates their health benefits”, a largely debated issue is to establish whether isoflavones only act through their phytoestrogenic properties or whether ER-independent mechanisms of action may also play a role. Isoflavones have been reported to modulate steroid biosynthesis, transport and metabolism, as well as carcinogen activation and detoxification, to inhibit cell proliferation induced by growth factors, to induce cell cycle arrest or apoptosis, to favour cell differentiation, to reduce oxidative stress or to inhibit angiogenesis, cell invasiveness and metastasis. They may act through modulation of cell signalling (direct binding to nuclear receptors, modification of the phosphorylation state of some signal transduction proteins), regulation of gene expression and/or specific inhibition of some key enzyme activities.
Isoflavones and the prevention of breast and prostate cancer

ES83

The mechanisms of action of isoflavones are reviewed here in the context of breast and prostate cancer. Table 1 summarizes the most relevant studies that have been published for each putative mechanism of action and notes whether in vivo data exist or whether the mechanism has only been observed in vitro. In vitro studies using isoflavone concentrations up to 10 μM have been distinguished from studies using higher pharmacological concentrations.

The major focus in isoflavone research so far lies on the modulation of steroid hormone receptor signalling. Estrogens regulate many physiological processes in hormone-dependent tissues, including cell growth and differentiation, apoptosis and tissue-specific gene regulation, but also influence the pathological processes of hormone-dependent diseases, such as breast and prostate cancers. The biological actions of estrogens are mediated by the binding to one of the two specific nuclear receptors, ERα and ERβ (100), which can induce gene transcription of estrogen-responsive target genes. A general hypothesis is that estrogens acting via ERα exert strong proliferation stimulatory effects while those interacting with ERβ tend to reduce this stimulation. Furthermore, ERβ has been shown to repress ERα-controlled transcription (88,89). Cell response would therefore depend on the balance between ERα and ERβ expression levels within a given cell type. This balance is altered in favour of ERα during tumour progression (90), emphasizing the protective role of ERβ signalling and the usefulness of ERβ-selective agonists in cancer prevention.

Eight in vitro and in vivo studies consistently reported a downregulation of ERα and an upregulation of ERβ mRNA and protein levels by genistein at 1–10 μM in breast cancer cell lines (91–93). A decrease in ERα protein expression was also observed in mammary tumours of Sprague–Dawley rats after consumption of a soy extract (94). In the dorsolateral prostate of rats and mice, exposure to dietary genistein (≥ 25 ppm for rats; 500 μg/g bw for mice) resulted in a downregulation of ERα and ERβ mRNA and protein expression (95–97).

Activation of ERs is an established effect of isoflavones that has been documented in the low nanomolar range, concentrations commonly achieved at nutritional levels of soy isoflavone intake. It has been shown in vitro that genistein has an agonist activity for both ER subtypes, but its affinity for ERβ is considerably greater than for ERα, with binding affinities of 8.4 nM and 145 nM, respectively (98,99). For daidzein, the corresponding values are 100 nM and 420 nM, indicating a much lower affinity for these receptors (98,99). The transactivating functions of ERα and ERβ are mediated by two transcription activation functions (AF) located in the ligand-binding domain, AF-1 (N-terminal) and AF-2 (C-terminal). AF-1 is very active in ERα on a variety of estrogen-responsive promoters, but minimal in ERβ, whereas AF-2-mediated transcriptional activities of ERs are dependent on recruitment and interactions with coactivator proteins (coactivators and corepressors) to estrogen-responsive promoters (100). The conformational change of the AF-2 transactivation helix induced by the formation of the ERβ-genistein complex is closer to that induced by ER antagonists than by ER agonists and could therefore account for the partial agonistic behaviour of genistein (101).

The higher affinity of isoflavones for ERβ is paralleled by their ability to activate transcription with ERβ at lower concentrations than with ERα (102). Genistein, daidzein and equol were reported to increase the binding rate of ERs to estrogen responsive elements (ERE), with a more prominent effect on ERβ than ERα. The concentrations of genistein, daidzein and equol which would increase this binding rate by 50% were determined to be 30 nM, 350 nM and 400 nM for ERβ and 15 μM, > 300 μM and 3.5 μM for ERα, respectively (103).

The activation of ERs by isoflavones subsequently lead to a modulation of the expression of their target genes, and thus, to a modulation of cellular processes such as proliferation and apoptosis. Well-known target genes for the ERs are PR, p52, bcl-2 and cyclin D1 (104,105). PR mRNA and protein levels were shown to be upregulated by isoflavones in the majority of the in vitro and in vivo studies. In MCF-7 cells, an upregulation was observed with 1–10 μM genistein (106), and in premenopausal cysnomolous macaques and ovariectomised athymic nude mice implanted with MCF-7 cells, the doses ranged between 240 and 750 ppm in the diet (106,107). In contrast, a natural soy extract (0.7% in the diet), containing 12% isoflavones and 35% saponins, decreased PR protein expression in mammary tumours of female Sprague–Dawley rats (94). Furthermore, soy isoflavones stimulated the expression of the ER target gene pS2 in breast cells, as shown in twelve in vivo and in vitro studies. As for the modulation of PR, low isoflavone concentrations (between 0.001 and 10 μM) were effective in vitro in MCF-7 cancer cells (106,108,109), whereas in vivo doses above 500 ppm in the diet in mouse xenograft models or 45 mg daily in premenopausal women were used (55,66,110). Only one in vitro study reported a converse decrease in mRNA expression of pS2 in premenopausal cysnomolous macaques after administration of 240 ppm isoflavones in combination with 0.09 mg/g estradiol (107). Other ER target genes such as bcl-2 and cyclin D1 were also significantly increased in breast cells after genistein treatment. At 1 μM, it increased bcl-2 mRNA expression in MCF-7 cells (111,112). Moreover, 750 ppm genistein in the diet increased cyclin D1 mRNA expression in a mouse xenograft model (111). Increased transcriptional and translational levels of the aforementioned estrogen-responsive target genes rather suggest estrogen-agonistic activities of isoflavones in breast cancer cells.

Since the androgen receptor (AR) pathway plays a pivotal role in prostate cell growth, differentiation and function, agents that minimise or eliminate AR transactivation are considered useful to prevent and treat prostate cancer. Although genistein does not seem to act as a ligand for AR (113), it has been shown to exert anti-androgenic effects in prostate cells, and to downregulate the expression and secretion of the typical androgen-responsive gene PSA (111,115). The mechanisms underlying isoflavone anti-androgenic effects are still not entirely elucidated. In more than seven in vitro and in vivo studies, a decrease in AR expression at mRNA and protein levels was detected in prostate cells exposed to low isoflavone concentrations (0.1–1 μM in vitro; 250 ppm in diet in vivo) (96,113,116). Long-term soy protein isolate consumption also lowered AR expression in prostate of men with high prostate cancer risk (117). Isoflavones may also decrease androgen levels (118,119). Moreover, a direct binding of DHT by equol has been reported in vitro, as well as a stimulation of testosterone inactivation through intracellular glucuronidation by biochanin A (120,121). Interestingly, Bektic et al. demonstrated with the use of a pure-estrogen that the down-regulation of the AR was mediated by ErbB in LNCaP cells. A cross-talk between ER and AR was also described by
<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Prostate</th>
<th>Breast</th>
<th>References</th>
<th>Demonstrated in vitro with physiological doses</th>
<th>Demonstrated in vitro with supra-physiological doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>ER and AR pathway</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ER mRNA and protein expression</strong></td>
<td>Downregulation of ERα mRNA in prostate of rats fed Ge (250 ppm from conception to day 70, or 250–1000 ppm from day 56 to day 70) and in prostate of mice fed 500 μg Ge/g bw</td>
<td>Downregulation of ERα mRNA levels in MCF-7 breast cell lines exposed to 1–10 μM Ge</td>
<td>(91, 92, 95–97, 106, 184)</td>
<td>P</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Decrease of ERα protein expression in mammary tumours of SD rats fed a soy extract (0.7% in the diet)</td>
<td>(94)</td>
<td>B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Downregulation of ERβ mRNA in prostate of rats fed Ge (250 ppm from conception to day 70, or 250–1000 ppm from day 56 to day 70)</td>
<td>Upregulation of ERβ mRNA levels in breast cell lines exposed to 1–10 μM Ge</td>
<td>(92, 93, 95, 96)</td>
<td>P</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Soy protein isolate consumption (107 mg/d isoflavones) for 6 mo lowered AR but not ERβ protein expression levels in prostate of men at high prostate cancer risk</td>
<td></td>
<td>(117)</td>
<td>P</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Downregulation of AR mRNA in prostate of rats fed Ge (250 ppm from conception to day 70, or 250–1000 ppm from day 56 to day 70) or a phytoestrogen-rich diet (600 ppm); no effect of Ge (250 ppm in diet) on AR protein level in TRAMP mice prostate</td>
<td></td>
<td>(96, 180, 263)</td>
<td>P</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Downregulation of AR at the mRNA and protein level in LNCaP cells exposed to Ge (0.1–1 μM); this effect was abolished by the pure antiestrogen ICI164 384, suggesting an action via ERβ. Da (up to 50 μM) had no effect</td>
<td></td>
<td>(113, 116)</td>
<td>P</td>
<td></td>
</tr>
<tr>
<td><strong>ER target gene expression (PR, pS2, cyclin D1, bcl-2)</strong></td>
<td>Downregulation of PR protein expression in the prostate of C57BL/6 mice fed with 500 μg Ge/g bw</td>
<td>Upregulation of PR mRNA and protein expression by Ge (1–10 μM in MCF-7 cells; 240–750 ppm in diet in premenopausal cynomolgus macaques and ovariectomized athymic nude mice implanted with MCF-7 cells)</td>
<td>(66, 97, 106, 107)</td>
<td>B, P</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Upregulation of pS2 mRNA and protein expression by Ge (0.001–10 μM in MCF-7 cells; 500 ppm in diet in ovariectomized athymic nude mice implanted with MCF-7 cells)</td>
<td>(55, 66, 106, 108–110)</td>
<td>B</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Upregulation of pS2 protein level in nipple aspirate fluid of premenopausal women supplemented with isoflavones (45 mg/d for 14 d)</td>
<td>(110)</td>
<td>B</td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Continued

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Prostate</th>
<th>Breast</th>
<th>References</th>
<th>Demonstrated in vitro with physiological doses</th>
<th>Demonstrated in vitro with supra-physiological doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Androgen-stimulated transcription (androgen responsive genes promote prostate cancer development and progression)</td>
<td>Ge does not function as a ligand agonist for AR in either PC3 or LNCaP cells; no effect of Ge (1 μM) was detected on the activation of AR-dependent transcription in reporter gene assays</td>
<td>Induction of cyclin D1 mRNA expression in a xenograft mouse model by Ge (750 ppm)</td>
<td>(66)</td>
<td>B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ge (10 μM) decreased AR binding to ARE, thereby inhibited transcription of androgen-responsive genes such as PSA in LNCaP cells</td>
<td>Induction of bcl-2 mRNA expression in MCF-7 cells exposed to Ge (1–10 μM)</td>
<td>(111,112)</td>
<td>B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Downregulation of PSA mRNA level in LNCaP cells exposed to Ge (1–5 μM); Ge (10 nm) dose-dependently decreased PSA secretion in both androgen-treated and untreated LNCaP cells (unknown mechanism); biochanin A (1–5 μM) significantly decreased testosterone-stimulated release of PSA by LNCaP cells through upregulation of UDPGT and intracellular glucuronidation of testosterone</td>
<td>(113,115,121)</td>
<td>P</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ge (10 μM) enhanced AR-driven gene expression (agonist R1881) through activation of the Raf-MEK-ERK signalling pathway in PC3 cells, as shown by the use of the specific inhibitor PD098059; Ge (0.5–5 μM) enhanced b-estradiol-induced PSA expression in LNCaP cells</td>
<td>(114,116)</td>
<td>P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthesis and metabolism of steroids</td>
<td>Inhibition of enzyme activity by 1–10 μM Ge and Da in several in vitro models, not investigated in prostate cells</td>
<td>Inhibition of enzyme activity by 1 μM Ge in T47D breast cancer cells</td>
<td>(69,122, 123,125)</td>
<td>X, B</td>
<td></td>
</tr>
<tr>
<td>17β-Hydroxysteroid dehydrogenase</td>
<td>Inhibition of enzyme activity by 1–10 μM Ge and Da in several in vitro models, not investigated in prostate cells</td>
<td></td>
<td>(69,123,264)</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>3β-Hydroxysteroid dehydrogenase</td>
<td>Inhibition of human aromatase in vitro by Ge at high doses (K = 123 μM), not investigated in prostate and breast cells</td>
<td></td>
<td>(124)</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Aromatase</td>
<td>Inhibition of enzyme activity by 1–10 μM Ge and Da in several in vitro models, not investigated in prostate cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanism</td>
<td>Prostate</td>
<td>Breast</td>
<td>References</td>
<td>Demonstrated in vivo</td>
<td>Demonstrated in vitro with physiological doses</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------</td>
<td>----------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>5α-Reductase activity</td>
<td>Inhibition of type 2 5α-reductase activity by Da and Ge (IC_{50} = 7 μM and IC_{50} = 20 μM) in vitro; not changed in rats fed isoflavone-rich diet (600 ppm) for 5 weeks; Ge above 20 μM inhibited 5α-reductase activity (20%) in rat prostate tissue homogenates</td>
<td>(118,265)</td>
<td>P</td>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Steroid sulfotransferase and sulfatase</td>
<td>Inhibition of hepatic estrogen sulfotransferase by Ge (0·5 μM) and equation (0·4 μM) in vitro; inhibition of steroid sulfatase by Da-sulfate (IC_{50} = 6 μM) and Da-disulfate (IC_{50} &lt; 1·5 μM) in vitro or in hamster liver extracts, not investigated in prostate and breast cells</td>
<td>(127–129)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estrogen levels</td>
<td>Inconsistent effects of soy or isoflavone consumption on circulating hormone profiles in women. 2 mg isoflavones/kg bw/d for 93 days decreased estrone sulfate plasma level in postmenopausal women. 40 mg Ge/d for 12 weeks decreased serum-free estradiol and estrone in premenopausal women. Other studies did not find significant changes in circulating sex steroid hormones. equol-producing premenopausal women showed reduced estrone and estrone sulfate plasma levels after isoflavone consumption (0·15, 1, 2 mg/d) in comparison to non-producers</td>
<td>(31,130,137)</td>
<td>B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovarian cycle length</td>
<td>Trend toward increased cycle length (32–200 mg isoflavones/d), but inconsistent results; mean follicular phase increased with 12-week supplementation of 40 mg Ge/d in young women</td>
<td>(130–132)</td>
<td>B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stimulation of hepatic synthesis and secretion of SHBG</td>
<td>Observed in vitro in HepG2 cells exposed to ≥ 5 μM Ge; in vivo studies showed an increasing effect in premenopausal women determined as 'equol-producers' after consumption of 0·15, 1 or 2 mg isoflavones/d and in postmenopausal women after consumption of 30 g soy milk (= 69 mg isoflavones)/d for 10 weeks; 2 mg isoflavones/kg bw/d for 93 days)</td>
<td>(31,133,135, 266–268)</td>
<td>B</td>
<td>B</td>
<td></td>
</tr>
<tr>
<td>Mechanism</td>
<td>Prostate</td>
<td>Breast</td>
<td>References</td>
<td>Demonstrated in vitro with physiological doses</td>
<td>Demonstrated in vitro with supra-physiological doses</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-------------------------------------</td>
<td>-----------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Androgen levels</td>
<td>Plasma testosterone and androstenedione levels significantly lowered in rats fed a phytoestrogen-rich diet (600 ppm) for 5 weeks; genistein (20 ppm in diet) reduced testosterone and DHT levels in male mice ortho- phically implanted with LNCaP cells; inconsistent effects of soy or isoflavone consumption on circulating hormone profiles in men. Most studies did not find significant changes in circulating sex steroid hormones</td>
<td></td>
<td>(117–119)</td>
<td>P</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eq specifically binds circulating and intracellular DHT with an apparent $K_d$ of 1.32 nM and prevent DHT’s biological actions</td>
<td></td>
<td>(120)</td>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Hypothalamic-pituitary-testicular (HPT) axis</td>
<td>No significant differences in plasma LH in rats fed a phytoestrogen-rich diet (600 ppm) for 5 weeks. Lack of significant effects of soy protein isolate supplementation on serum LH in men; 2-week-supplementation with clover phytoestrogens (240 mg/d) increased serum LH and modestly decreased serum testosterone concentrations in men with prostate cancer and induced testicular resistance to LH</td>
<td></td>
<td>(118,269,270)</td>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Cell cycle control and apoptosis</td>
<td>Cell cycle arrest</td>
<td>G2/M arrest observed with 5–10 μM Ge in breast cancer cell lines and ≥15 μM in non-neoplastic breast cells</td>
<td>(147–152)</td>
<td>B</td>
<td>P</td>
</tr>
<tr>
<td></td>
<td>Downregulation of cyclin B expression; inhibition of cdc2 activity</td>
<td>Observed in LNCaP cells exposed to high concentration of Ge (20–60 μM); not observed at 10 μM Ge in LNCaP cells</td>
<td>Observed in MCF-10F, MCF-7 and MDA-MB-231 cells exposed to high concentration of Ge (45–100 μM)</td>
<td>(148,149,152,155, 157,164,271)</td>
<td>P, B</td>
</tr>
<tr>
<td></td>
<td>Upregulation of cyclin-dependent inhibitors (p21&lt;sup&gt;WAF1&lt;/sup&gt;; p27&lt;sup&gt;KIP1&lt;/sup&gt;)</td>
<td>Observed in LNCaP cells exposed to high concentration of Ge (20–60 μM)</td>
<td>Observed in mammary gland of rats fed Ge or soy protein isolate (0.5 mg/kg bw) and in MCF-7, MDA-MB-231 and AU565 cells exposed to Ge (≥1 μM)</td>
<td>(148,149,155, 160–164)</td>
<td>B, B</td>
</tr>
<tr>
<td></td>
<td>Induction of apoptosis</td>
<td>Observed in PC3 and LNCaP cells exposed to high concentration of Ge (≥20–50 μM)</td>
<td>Observed in mammary gland of rats fed Ge or soy protein isolate (250 ppm Ge or 394 ppm isoflavones in diet; observed in MCF-7 and MDA-MB-231 cells exposed to high Ge concentration (≥25 μM)</td>
<td>(3,86,112,160, 163,271)</td>
<td>B, P</td>
</tr>
<tr>
<td>Mechanism</td>
<td>Prostate</td>
<td>Breast</td>
<td>References</td>
<td>Demonstrated in vivo with physiological doses</td>
<td>Demonstrated in vitro with supra-physiological doses</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Downregulation of antiapoptotic Bcl-2, Bcl-x and upregulation of prosapop</td>
<td>Not modified in prostate cancer cells exposed to Ge concentration lower than 40 μM</td>
<td>Observed in mammary gland of rats fed Ge or soy protein isolate (250 ppm Ge or 394 ppm iso-flavones in diet) and in MDA-MB-231 and 184-BS/HER cells exposed to Ge (≥ 5 μM)</td>
<td>(3,112,148,160, 163,272)</td>
<td>P</td>
<td></td>
</tr>
<tr>
<td>opotic Bax, Bak, Bok expression</td>
<td></td>
<td>Inhibition of chymotrypsin-like activity (≥ 30%) of purified proteasome from LNCaP cell extracts by 1 μM Ge, but much higher Ge concentration needed to inhibit proteasome in intact LNCaP cells (IC50 = 70 μM)</td>
<td>(165)</td>
<td>P, B</td>
<td></td>
</tr>
<tr>
<td>Inhibition of proteasome activity (which plays essential role in promoting</td>
<td>Inhibition of chymotrypsin-like activity (≥ 30%) of purified proteasome from MCF-7 cell extracts by 1 μM Ge, but much higher Ge concentration needed to inhibit the proteasome in intact MCF-7 cells (IC50 = 65 μM)</td>
<td>Reduced vessel density and decreased protein levels of VEGF and TGFβ in tumours and serum from nude mice implanted with MDA-MB-231 and MCF-7 cells and treated by s.c. injections of Ge (0.1–0.5 mg/kg bw)</td>
<td>(147,154)</td>
<td>P, B</td>
<td></td>
</tr>
<tr>
<td>tumour cell proliferation and protecting tumour cells from apoptosis)</td>
<td></td>
<td>No effect on VEGF and VEGFR expression in prostate of TRAMP mice fed 250 ppm Ge</td>
<td>(180)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angiogenesis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microvessel density in tumours</td>
<td>Reduced vessel density in SCID mice inoculated with LNCaP cells and fed diets supplemented with three levels of soy phytochemical concentrate (415 ppm, 756 ppm, 2120 ppm iso-flavones)</td>
<td>Reduced vessel density and decreased protein levels of VEGF and TGFβ in tumours and serum from nude mice implanted with MDA-MB-231 and MCF-7 cells and treated by s.c. injections of Ge (0.1–0.5 mg/kg bw)</td>
<td>(147,154)</td>
<td>P, B</td>
<td></td>
</tr>
<tr>
<td>Invasion and metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell adhesion and migration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matrigel invasion</td>
<td>Reduction of the invasive potential and upregulation of KAI1 mRNA and protein levels in TRAMP-C2 prostate cancer cells exposed to 5 μM Ge; induction of PC-3 and DU-145 cell invasion through Matrigel by plasminogen is counteracted by Ge (dose unknown)</td>
<td>Induction of MDA-MB-231 cells invasion through Matrigel by arachidonic acid or DHA is reversed by Ge (10 μM)</td>
<td>(140,170,171)</td>
<td>P, B</td>
<td></td>
</tr>
<tr>
<td>Matrix metalloproteinases (MMP)</td>
<td>Inhibition of MMP-2 expression in PC3 and LNCaP cells by Ge (≥ 18 μM); Ge (≥ 10 μM) inhibited TGFβ-β-mediated induction of MMP-2 in six cell lines including normal, early cancer and established cancer prostate cell lines, possibly through inhibition of p38 MAPK</td>
<td>Downregulation of MMP-9 and upregulation of TGF-1 mRNA expression in tumours from nude mice implanted with MDA-MB-231 or MCF-7 cells and treated by s.c. injections of Ge (0.1–0.5 mg/kg bw)</td>
<td>(154,172–174)</td>
<td>B</td>
<td></td>
</tr>
<tr>
<td>Osteopontin</td>
<td>Ge (250 or 500 mg Ge/kg bw) reduced OPN mRNA levels in TRAMP mice prostates displaying advanced prostate cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanism</td>
<td>Prostate</td>
<td>Breast</td>
<td>References</td>
<td>Demonstrated in vivo with physiological doses</td>
<td>Demonstrated in vitro with supra-physiological doses</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
<td>------------</td>
<td>-----------------------------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td><strong>Regulation of cell signalling pathways</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Growth factors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EGF signalling</strong></td>
<td>Downregulation of EGFR expression in rat and TRAMP mice prostate with 250–1000 ppm Ge in the diet; Not seen in LNCaP cells</td>
<td>Initial upregulation of EGFR protein in mammary gland of young rats, pre-pubertally treated with Ge (250 ppm in diet or 500 μg/g bw) and subsequent downregulation of EGFR in mammary gland (stimulation of early differentiation)</td>
<td>(179–183)</td>
<td>P, B</td>
<td></td>
</tr>
<tr>
<td><strong>IGF-1 signalling</strong></td>
<td>Inhibition of EGF-stimulated growth of LNCaP and DU145 cells by Ge and Da (15–60 μM), without inhibition of EGFR autophosphorylation</td>
<td>Inhibition of DNA synthesis by 0.1 μM Ge in presence of 1 ng/ml EGF; induction of DNA synthesis by 1–10 μM Ge in presence of 1 ng/ml EGF in breast cancer cells</td>
<td>(68,176)</td>
<td>B</td>
<td>P</td>
</tr>
<tr>
<td><strong>IGF-1 signalling</strong></td>
<td><strong>Downregulation of IGF-1R but not of IGF-1 in TRAMP mice fed 250 ppm genistein</strong></td>
<td>Upregulation of IGF-1R, IRS-1 mRNA and protein expression in MCF-7 cells by 1 μM Ge</td>
<td>(180,184)</td>
<td>P</td>
<td>B</td>
</tr>
<tr>
<td><strong>IGF-1 signalling</strong></td>
<td>Inhibition of IGF-1 stimulated proliferation of rat prostatic cancer cells by Ge (10 μM)</td>
<td>Induction of IGF-1-induced DNA synthesis by 0.1–10 μM Ge; inhibition of IGF-1-stimulated proliferation of MCF-7 cells by Ge (&lt;25 μM)</td>
<td>(68,177)</td>
<td>P, B</td>
<td></td>
</tr>
<tr>
<td><strong>IGF-1 signalling</strong></td>
<td>Positive association between soy protein intake (food frequency questionnaire) and serum IGF-1 levels in Asian men</td>
<td>No significant association between soy product and soy isoflavone intake and serum IGF-1 in Asian premenopausal and European pre- and postmenopausal women</td>
<td>(186–188,192)</td>
<td>P, B</td>
<td></td>
</tr>
<tr>
<td><strong>IGF-1 signalling</strong></td>
<td>40 g soy protein for 3 months increased IGF-1 serum levels stronger than milk protein; 83 mg/d of soy isoflavone for 12 mo did not modulate serum IGF in old men; 3–6 mo supplementation with 100 mg/d of soy isoflavone did not significantly change serum levels of IGF-1 or IGFBP-3 levels in men with prostate cancer</td>
<td>Increased IGF-1 plasma levels after 40 g soy protein intake for 3 months in postmenopausal women; 80 mg total phytoestrogens daily increased IGF-1 and IGFBP-3 plasma levels after 1 week in healthy women; low isoflavone-enriched diet (1 mg/kg bw –d) for 3 months increased IGF-1 and IGFBP-3 serum levels in pre-menopausal women, high isoflavone-enriched diet (2 mg/kg bw –d) for 3 months decreased IGF-1 and IGFBP-3 serum levels in post-menopausal women</td>
<td>(189–191, 193–195)</td>
<td>P, B</td>
<td></td>
</tr>
<tr>
<td><strong>IGF-1 signalling</strong></td>
<td>Decreased serum IGF-1 levels in Han:SPRD-cy rats fed a soy protein-based diet for 6 weeks and in mice after supplementation with soy protein isolate (20% in diet) and soy phytochemical concentrate (1% in diet)</td>
<td></td>
<td>(147,185)</td>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Mechanism</td>
<td>Prostate</td>
<td>Breast</td>
<td>References</td>
<td>Demonstrated in vitro with physiological doses</td>
<td>Demonstrated in vitro with supra-physiological doses</td>
</tr>
<tr>
<td>-----------</td>
<td>----------</td>
<td>--------</td>
<td>------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Akt and NFκB pathways and their cross-talk</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Akt pathway (activation promotes cell survival, by inactivation of pro-apoptotic factors; also regulates NFκB pathway)</td>
<td>Inhibition of Akt phosphorylation by 10 μM Ge in DU145 cells</td>
<td>Inhibition of Akt phosphorylation in MCF-7 cells exposed to Ge (&gt;1 μM)</td>
<td>(161,196)</td>
<td>P, B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inhibition of Akt kinase activity by 50 μM Ge in non-stimulated PC3 cells, and abrogation of EGF-stimulated Akt activation</td>
<td>Decrease in phosphorylated Akt1 and total Akt1 in non-stimulated MDA-MB-231 cells exposed to Ge (30 μM); abrogation of EGF-stimulated Akt activation by Ge (50 μM) in MDA-MB-231 cells</td>
<td>(199,273)</td>
<td>P, B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Incorporation of Ge in the diet (250 and 1000 ppm) of transgenic male TRAMP/FVB mice resulted in a drastic reduction of Akt activation, subsequent activation of GSK-3β, culminating in a dose-dependent post-transcriptional reduction in cyclin D1 levels, and maintenance of the cadherin-1 complex via downregulation of snail-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Induction of PTEN gene expression in PC-3 and LNCaP cells by Ge (20 μM). Decreased expression of VEGF, ERα and ERβ genes may be via repression of Akt pathway by PTEN</td>
<td>Induction of PTEN protein expression in SD rats fed Ge or soy protein isolate (250 ppm Ge or 394 ppm isoflavones in diet) and in MCF-7 cells exposed to Ge (&gt;0.1 μM)</td>
<td>(161,163,168)</td>
<td>B, B</td>
<td>P</td>
</tr>
<tr>
<td>NFκB (control of cell growth, differentiation, apoptosis, inflammation, stress response)</td>
<td>Inhibition of iκB phosphorylation by Ge (50 μM) in LNCaP and PC3 cells</td>
<td>Induction of iκB protein expression in MCF-7 cells by 100 μM Ge</td>
<td>(86,165,201, 273,274)</td>
<td>P, B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inhibition of NFκB DNA-binding activity by Ge (&gt;30 μM) in LNCaP and PC3 cells</td>
<td>Inhibition of NFκB DNA-binding activity in MDA-MB-231 breast cancer cells exposed to Ge (&gt;30 μM)</td>
<td>(86,199,201, 273,274)</td>
<td>P, B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ge (&gt;30 μM) abrogated NFκB activation by DNA damaging agents (H₂O₂ and TNF-α) in LNCaP and PC3 cells</td>
<td>Ge (50 μM) abrogated EGF- and AKT-induced NFκB activation in MDA-MB-231 breast cancer cells</td>
<td>(86,199,201, 273,274)</td>
<td>P, B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inhibition of arachidonic acid-stimulated NFκB mRNA expression by Ge (2-5 μM) in MDA-MB-231 cells</td>
<td></td>
<td></td>
<td>B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.5 μM Ge activated NFκB and elevated expression of Mn-SOD through activation of ERK1/2 in MCF-7 cells</td>
<td></td>
<td></td>
<td>B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ge (&gt;10 μM) and Da (100 μM) inhibited constitutively active transcription factors NFκB and AP-1 in highly invasive MDA-MB-231 cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanism</td>
<td>Prostate</td>
<td>Breast</td>
<td>References</td>
<td>Demonstrated in vitro with physiological doses</td>
<td>Demonstrated in vitro with supra-physiological doses</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------</td>
<td>-------------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td><strong>MAPK signalling</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JNK</td>
<td>Induction of activation of JNK protein by Ge (0.1–25 μM) in MCF-7 cells</td>
<td>(111)</td>
<td>B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p38</td>
<td>Increase of p38 phosphorylation by Ge (0.5–45 μM) in MCF-10F cells</td>
<td>(158)</td>
<td>B</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ERK1/2</strong></td>
<td>Decrease of phosphorylated ERK1/2 protein in prostate of TRAMP mice fed Ge (250 ppm in diet)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ge (1–10 μM) increased ERK1/2 activity in non-tumorigenic prostate epithelial cells RWPE-1 cells via an estrogenic-dependent mechanism and in tumorigenic LNCaP and PC3 cells, while supra-physiological concentrations (&gt; 25 μM) decreased ERK1/2 signalling; glycitein (0.01–100 μM) induces sustained ERK1/2 activation in RWPE-1 cells. This activation was independent of estrogen and androgen receptor signalling but dependent on VEGFR signalling</td>
<td>(114,177, 204,205)</td>
<td>P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c-jun, c-fos (member of the AP-1 protein)</td>
<td>Decrease of the c-jun:c-fos mRNA ratio in nude mice implanted with MDA-MB-231 or MCF-7 cells and treated by s.c. injections of Ge (0.1–0.5 mg/kg bw)</td>
<td>(154)</td>
<td>B</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PPARγ pathway</strong></td>
<td>Ge binds a human full-length PPARγ receptor expressed in bacteria (Kᵢ = 5.7 μM)</td>
<td></td>
<td>(139)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ge (1–10 μM) stimulated PPAR γ-directed gene expression in various cell types (T47D, MDA-MB-231, K5483, RAW 264.7, HUVEC cells)</td>
<td></td>
<td>(76,138)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Induction of PPARγ mRNA expression in MDA-MB-231 cells exposed to Ge (2.5 μM) in combination with PUFAs</td>
<td></td>
<td>(140)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Continued

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Prostate</th>
<th>Breast</th>
<th>References</th>
<th>Demonstrated in vitro with physiological doses</th>
<th>Demonstrated in vitro with supra-physiological doses</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antioxidant activities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Free radical scavenging</strong></td>
<td>Oxidative metabolites of genistein and daidzein, as well as genistein and</td>
<td>(211–213)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>equol inhibited in vitro formation of conjugated dienes and TBARS in</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>copper-induced LDL oxidation (EC_{50} &lt; 10 µM), not investigated in</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>prostate and breast cells. Ge inhibited TPA-stimulated H_{2}O_{2}</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>production in human polymorphonuclear leukocytes (IC_{50} = 14.8 µM) and</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HL-60 cells (IC_{50} = 30.2 µM). Ge (&gt;10 µM) scavenged H_{2}O_{2} in a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>cell-free system. Ge (100–200 µM) inhibited O_{2} formation. Ge (0.1–</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 µM) suppresses TPA-mediated H_{2}O_{2} formation in mouse skin, not</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>investigated in prostate and breast cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antioxidant enzyme regulation</strong></td>
<td>Upregulation of GPx mRNA expression in LNCaP and PC-3 cells exposed to</td>
<td>(250)</td>
<td>P</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ge (100 µM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upregulation by Ge of MT-1X mRNA and protein expression (1–30 µM),</td>
<td>(214)</td>
<td>P</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GSR mRNA expression (10–30 µM) and mGST-1 mRNA expression (30 µM) in</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LNCaP cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Induction of Mn-SOD mRNA expression in MCF-7 cells exposed to 0.5 µM Ge</td>
<td>(203)</td>
<td>B</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Isoflavone supplementation (138 mg/d) for 24 days increased Cu/Zn-SOD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>activities in erythrocytes of breast cancer survivors</td>
<td>(215)</td>
<td>B</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Xenobiotic metabolism</strong></td>
<td>Inhibition of CYP2C and CYP3A protein expression in hepatic microsomes</td>
<td>Inhibition of constitutive and DMBA-induced CYP1A1, 1A2, 1B1 mRNA and</td>
<td>(216,275)</td>
<td>B, X</td>
<td></td>
</tr>
<tr>
<td>Phase I</td>
<td>of SD rats fed Ge (1250 ppm in diet)</td>
<td>protein expression in mammary glands of SD rats fed isoflavones (430 ppm in diet)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inhibition of CYP1A2 activity in healthy volunteers (10 pre-menopausal</td>
<td>(218)</td>
<td>B</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>females and 10 males supplemented with Da (400 mg/d for 10 days)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanism</td>
<td>References</td>
<td>Demonstrated in vitro with physiological doses</td>
<td>Demonstrated in vitro with supra-physiological doses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>------------</td>
<td>-----------------------------------------------</td>
<td>-------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Phase II</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhibition of CYP1A1 and 1B1 activities in MCF-7 cells exposed to Ge ($K_{i} = 15-4 \mu M$ and $K_{i} = 0-7 \mu M$, respectively)</td>
<td>(217) B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Induction of GSTP1 mRNA, protein expression and enzyme activity in non-tumourigenic MCF-10A cells exposed to Ge (1–30 \mu M)</td>
<td>(219) B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Induction of quinone reductase (QR) mRNA and protein expression in MDA-MB-231 and MCF-7 cells exposed to 10 \mu M Ge</td>
<td>(220) B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhibition of COMT activity in cytosolic fractions of human mammary tissues exposed to 30 \mu M Ge</td>
<td>(276) B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Induction of liver GPx, QR, kidney GST, colon QR and colon UDPGT activity in female SD rats fed isoflavones (0-81 mg/g diet)</td>
<td>(277) X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Induction of UDPGT activity in LNCaP cells exposed to 5 \mu M Ge</td>
<td>(121) P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhibition of SULT1A1 activity in human liver tissues by Ge ($IC_{50} = 2 \mu M$)</td>
<td>(278) X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DNA repair</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time- and concentration-dependent upregulation of BRCA1 and BRCA2 protein levels in LNCaP and DU145 cells exposed to Ge (0-5–7.5 \mu M)</td>
<td>(209) B, P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upregulation of BRCA1 and BRCA2 protein levels in MCF-7 and T47D cells exposed to Ge (0.5–1 \mu M)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upregulation of BRCA2 mRNA levels in ovariectomised rats fed isoflavone-formulated Soylife (8 \mu g/g bw); upregulation of BRCA1 protein levels in rats fed Ge (1.25–3.3 \mu g/g bw)</td>
<td>(51,210) B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vitamin D metabolism</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthesis of the antiproliferative and prodifferentiative metabolite 1,25-dihydroxy-vitamin D3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inhibition of topoisomerase II (maintains DNA structure)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhibition of topoisomerase II by Ge (&gt;20 \mu M) in vitro, not investigated in prostate and breast cells</td>
<td>(223) X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Telomeres</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Repression of hTERT transcriptional activity in PC3 and DU145 cells exposed to Ge (50 \mu M)</td>
<td>(196,224) B, P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

P, prostate; B, breast; X, other cells/tissues.
Davis et al.\(^{116}\), who reported that genistein (0.5–5 \(\mu\)M) enhanced 17\(\beta\)-estradiol-induced PSA expression in LNCaP cells. At a slightly higher concentration (10 \(\mu\)M), genistein stimulated AR-driven gene expression through activation of the Raf-MEK-ERK signalling pathway in PC3 cells, again demonstrating the critical importance of the dose. It is noteworthy that daidzein, at concentrations up to 50 \(\mu\)M, did not modulate PSA or AR protein levels in LNCaP cells\(^{116}\).

Because steroid hormone levels influence the development of hormone-dependent cancers, the research also focused on the impact of isoflavones in the synthesis and metabolism of steroids. However, the potency of isoflavones to inhibit some key enzymes involved, such as 17\(\beta\)-hydroxysteroid dehydrogenase, 3\(\beta\)-hydroxysteroid dehydrogenase, aromatase, and 5\(\alpha\)-reductase, in humans is questionable. Although the inhibition of 17\(\beta\)-hydroxysteroid dehydrogenase, 3\(\beta\)-hydroxysteroid dehydrogenase and 5\(\alpha\) reductase was observed at low doses of 1–10 \(\mu\)M, this was mostly shown in platelet microsomes or using isolated human enzymes\(^{69,122–124}\). Data for enzyme inhibition in breast and prostate cells are still limited. Makela et al. reported an inhibition of 17\(\beta\)-hydroxysteroid dehydrogenase with 1 \(\mu\)M genistein in breast cancer cells\(^{125}\). In rat prostate homogenates an inhibition of 5\(\alpha\)-reductase activity was observed after treatment with 20 \(\mu\)M genistein\(^{126}\). Genistin and equol at nanomolar concentrations also showed inhibition of steroid sulfotransferases \textit{in vitro}, whereas daidzein sulfates at 1.5–6 \(\mu\)M inhibited steroid sulfatase significantly\(^{127–129}\). Finally, a favourable reduction in serum hormone levels in women and men as well as the stimulation of SHBG and the prolongation of the menstrual cycle in women supplemented with soy isoflavones have been observed in some studies, even if results are still quite inconsistent\(^{31,117–120,130–135}\). It should be noticed that these mechanisms in women were highly dependent on factors such as the menopausal status, the level of endogenous estrogens, the intake of oral contraceptives and the gut microbial composition. In a postmenopausal primate model as well as in postmenopausal women isoflavone supplementation (129 mg/1800 kcal and 2 mg/kg bw/d, respectively) decreased serum hormones such as estrone-sulfate, estrone, estradiol and increased urinary 2-hydroxyestrone levels as well as the urinary 2:16α-hydroxyestrone ratio\(^{134,135}\). Furthermore, it was shown that isoflavones (60, 120 and 240 mg/d) lowered serum estrone and estradiol concentrations significantly in a high estradiol environment but not in a low estradiol environment in postmenopausal primates\(^{107}\). Studies in premenopausal women showed inconsistent results. While no changes in menstrual cycle length and serum hormones were observed after long-term intervention with high isoflavone doses (50 mg/d for 2 years or 100 mg/d for 1 year)\(^{17,136}\), a short-term intervention of 12 weeks with 40 mg genistein/d and of 93 days with 10, 64 and 128 mg isoflavones/kg bw/d increased menstrual cycle length and decreased serum free estradiol, estrone, DHEA-sulfate, follicle stimulating hormone (FSH) and luteinising hormone (LH) levels\(^{130,137}\). It was also demonstrated that gut microflora influenced serum hormone levels of premenopausal women, showing that equol-producers had lower serum hormone concentrations after isoflavone supplementation than non-producers\(^{31}\).

Recent \textit{in vitro} studies suggest that isoflavones may also act through activation of other nuclear receptors than ER and AR. Dang et al. showed for the first time in 2003 that genistein was able to bind a human full-length PPAR\(\gamma\) receptor expressed in bacteria, with a \(K_d\) of 5.7 \( \mu \)M, comparable to that of some known PPAR\(\gamma\) ligands\(^{76}\). Furthermore, genistein dose-dependently (5–50 \(\mu\)M) stimulated PPAR\(\gamma\)-directed gene expression in T47D and MDA-MD-231 breast cancer cells and other cell types transfected with PPRE-luciferase construct and expression plasmids encoding human PPAR\(\gamma\)\(^{76,130}\). A similar reporter assay and siRNA targeting approach confirmed the PPAR\(\gamma\) agonist effect of genistein in HUVEC cells at a low physiological dose (1 \(\mu\)M)\(^{130}\). Genistein (2.5 \(\mu\)M) in combination with polyunsaturated fatty acids also induced PPAR\(\gamma\) mRNA expression in MDA-MB-231 cells\(^{140}\). PPAR\(\gamma\) agonists are known to act as modulators of cell cycle and estrogenic actions, to inhibit the proliferation of cultured human breast and prostate cancer cells, and to modify breast epithelial gene expression leading to a more differentiated and less-malignant state\(^{141–144}\). Accumulating evidence also suggests that PPAR\(\gamma\) may act as a tumour suppressor in prostate cancer. Phase II clinical trials using PPAR\(\gamma\) ligands have been recently carried out as novel therapy for advanced breast and prostate cancer patients\(^{143,145,146}\). A balance between ER and PPAR\(\gamma\) activation, depending on the genistein concentration and the levels of ER and PPAR\(\gamma\) in the tissue may thus explain some of the effects of isoflavones\(^{145}\).

Isoflavones are capable of inhibiting proliferation by inducing G1 and/or G2/M cell cycle arrest in breast and prostate cancer cells\(^{3,147,148}\). While concentrations ranging between 5 and 10 \(\mu\)M genistein inhibited cell cycle in breast cancer cell lines, pharmacological doses of 20–60 \(\mu\)M were required to achieve the same effect in prostate cancer cells\(^{147,149–152}\). Progression in the cell cycle depends on the activity of a functional complex formed between cyclin B1 and the cyclin-dependent kinase (cdk) Cdc2\(^{99,153}\). A significant downregulation of cyclin B1 and Cdc2 levels by genistein has been consistently observed in breast and prostate models \textit{in vitro}, but only at high doses (20–100 \(\mu\)M)\(^{154–157}\). In order to achieve the inhibition of Cdc2 protein expression, supra-physiological doses of genistein (≥45 \(\mu\)M) were also required in non-tumour breast cells as well as in breast and prostate cancer cells\(^{152,155}\). In addition, progression to mitosis can be affected by the phosphorylation status of Cdc2 mediated by Wee-1 protein kinases\(^{156}\). Exposure of the non-tumorigenic breast cell line MCF-10F to 45 \(\mu\)M genistein resulted in an increase in phosphorylated Cdc2 protein levels\(^{158}\), and in TRAMP C2 prostate cells an increase in protein expression of protein kinase Mty-1 was observed upon exposure to 50 \(\mu\)M genistein\(^{156}\). In contrast, the other protein kinase Wee-1 was suppressed\(^{156}\). On the other hand, dephosphorylation of Cdc2 by the phosphatase Cdc25C increases the kinase activity of the cyclin B1–Cdc2 complex in the M phase\(^{159}\). The group of Frey et al. demonstrated a significant downregulation of Cdc25C protein expression using 50 \(\mu\)M genistein in the non-tumorigenic breast cell line MCF-10F\(^{152}\). In summary, the effect on cdc2 phosphorylation was only observed at high genistein concentrations.

Cell cycle progression is also affected by the levels of cdk inhibitors p21\(^{\text{WAF1}}\) and p27\(^{\text{KIP1}}\), which were significantly upregulated upon genistein supplementation in breast and prostate cells. Eleven \textit{in vivo} and \textit{in vitro} studies on breast cancer showed a genistein-induced upregulation of p21\(^{\text{WAF1}}\).
Isoflavones and the prevention of breast and prostate cancer

In the context of dietary isoflavones, concentrations (≥0.5 mg/kg bw in mouse xenograft model, 250 ppm in the diet in Sprague–Dawley rats, ≥5 μM in breast cell lines MCF-7, MDA-MB-231) and p27kip1 mRNA and protein levels (≥1 μM in breast cell lines MCF-7, MDA-MB-231) in prostate cancer cells, an upregulation of p21WAF1 and p27kip1 mRNA and protein levels was consistently observed upon exposure to high concentrations of genistein (20–60 μM), as summarised from eight in vitro studies (149,155,164).

In addition to the inhibition of cell proliferation, isoflavones can induce apoptosis in human breast and prostate cells at concentrations over 25 μM and 20 μM, respectively (3,106). One in vivo study reported isoflavone-induced apoptosis in mammary glands of Sprague–Dawley rats (250 ppm genistein or 394 ppm mixed isoflavones) (163). Pro-apoptotic proteins Bak and Bok were shown to be upregulated in breast cell culture models or rat mammary glands by genistein at respectively concentrations of 5 μM, 25 μM or 250 ppm in the diet (112,160,163), while anti-apoptotic proteins Bcl-2 and Bcl-xL were downregulated at genistein concentrations (≥5 μM in vitro (MDA-MB-231, 184-B5/HER)) (112,160). Data regarding apoptosis-associated proteins and their modulation by isoflavones in prostate cells are limited. However, it was shown by three different groups that genistein concentrations above 40 μM were necessary to upregulate Bax and downregulate Bcl-xL and Bcl-2 in vitro (148,165,166). Furthermore, expression of cell cycle regulators such as p53, PTEN, p21kip1, and p27kip1, also involved in the apoptotic process, were modulated by isoflavones. The modulation of p21kip1 (161), p27kip1 (154), and p27kip1 (163) has been described above. From two in vitro studies reporting p53 modulation in breast cancer and two studies (one in vivo, one in vitro) reporting p53 modulation in prostate cancer, it was shown that only high genistein concentrations (≥25 μM) were able to increase this protein expression (111,167). In contrast, the tumour suppressor gene PTEN was upregulated after incubating MCF-7 cells with a very low concentration of 0.1 ng genistein (161). In vivo, doses of 250 ppm genistein or 394 ppm mixed isoflavones were also reported to induce PTEN protein expression in the mammary gland (163). An induction of PTEN gene expression by genistein (20 μM) was similarly described for LNCaP and PC3 prostate cells (168).

Inhibition of angiogenesis is another biological effect of isoflavones that has been reported in vivo in the context of breast and prostate cancer. Genistein (0.1–0.5 mg/kg bw) or a soy phytochemical concentrate significantly reduced vessel density in breast and prostate mouse xenografts (147,154). In highly invasive MDA-MB-231 breast cancer cells, 10 μM genistein suppressed cell migration as well as cell proliferation (167). The group of El Touny observed a genistein-induced upregulation of PTEN gene expression (111) in the prostate of TRAMP mice (112). In contrast, an increase in the expression of PTEN in the mammary gland (163) was observed following administration of 250 ppm genistein (184). While IGF-I stimulates proliferation of rat prostate cancer cells, an inhibition of 10 μM genistein (177), physiological genistein concentrations (0.1–10 μM) further increased IGF-I-stimulated growth (176), whereas the effect in MCF-7 breast cells is dependent on the genistein concentration added, showing growth inhibition with 0.1 μM and promotion with 1–10 μM (168).

In the prostate of TRAMP mice, a decrease in IGF-1R protein was observed following administration of 250 ppm genistein in the diet (180). In contrast, an in vivo study in MCF-7 breast cancer cells reported an increase in IGF-1R protein expression after exposure to 1 μM genistein (184). While IGF-1-stimulated proliferation of rat prostate cancer cells was inhibited by 10 μM genistein (177), physiological genistein concentrations (0.1–10 μM) further increased IGF-1-stimulated growth of MCF-7 cells. Only pharmacological doses of genistein (≥25 μM) showed an inhibitory effect on breast cancer cell growth (168).

Decreased IGF-1 serum levels were detected in male rats and mice after administration of soy protein and soy isoflavone-enriched diets (147,185). However, contrasted effects of soy or isoflavones on IGF-1 were observed in human studies. Cross-sectional studies in Asian and European women showed no association with soy, isoflavones and soy protein intake and IGF-1 levels (186–188). Experimental studies in women gave controversial results. Consumption of 40 g soy protein for 3 months led to increased IGF-1 plasma levels in postmenopausal women (189). Again, increased plasma IGF-1 and IGFBP-3 concentrations were observed in women consuming 80 mg phytoestrogens (including soy isoflavones) (190) and in premenopausal women after consumption of a low-isoflavone enriched diet (1 mg/kg bw +d) (191). In contrast, a high-isoflavone diet (2 mg/kg bw +d) for 3 months resulted in decreased serum IGF-1 concentrations in postmenopausal women (191).
In men the effect of isoflavone supplementation on serum IGFI-1 levels was also inconsistent. A positive correlation was found between intake of soy protein and serum IGFI-1 levels in Asian and Caucasian men\(^{(192,193)}\) but two intervention studies showed no effect of soy isoflavones\(^{(194,195)}\).

Inhibition of the Akt signalling pathway through inhibition of Akt phosphorylation was observed in breast and prostate cell lines exposed to \(1\)–\(10 \mu M\) genistein\(^{(161,196)}\), as well as in male TRAMP/FVB mice fed with 250–1000 ppm genistein\(^{(197)}\). An abrogation of EGF-stimulated Akt activation was also observed with a high dose (50 \(\mu M\)) of genistein\(^{(198,199)}\). As PTEN expression is known to be upregulated in prostate and breast cells by low genistein concentrations, as described above, it may modulate the repression of the Akt pathway.

Furthermore it was shown that genistein concentrations above 10 \(\mu M\) inhibited the constitutively activated transcription factor NF-\(\kappa B\) in highly invasive MDA-MB-231 breast cells\(^{(169)}\). Pharmacological doses of genistein (\(>30 \mu M\)) inhibited NF-\(\kappa B\) DNA-binding activity and abrogated NF-\(\kappa B\) activation induced by DNA damaging agents, EGF and Akt in LNCaP, PC3 prostate and MDA-MB-231 breast cells\(^{(198–202)}\).

Moreover, protein expression of IkB, the inhibitor of NF-\(\kappa B\) in the cytosol, was induced in MCF-7 breast cancer cells by 100 \(\mu M\) genistein\(^{(165)}\). Conversely, an inhibition of IkB was reported for prostate cells in vitro\(^{(201)}\). These effects have been observed using very high isoflavone concentrations. However, Borras et al. recently reported that a dose as low as 0.5 \(\mu M\) genistein efficiently activated NF-\(\kappa B\) and subsequently elevated Mn-superoxide dismutase (SOD) expression in MCF-7 cells\(^{(203)}\).

Expression of different members of the MAPK cascade is modified by genistein in breast cells. Protein expression of JNK and p38 MAPK was increased when MCF-7 and MCF-10F cells were incubated with 0.1–45 \(\mu M\) genistein\(^{(11,158)}\). In contrast, ERK1/2 protein expression was decreased in MCF-10F cells when using a high genistein concentration (45 \(\mu M\))\(^{(158)}\) and in the prostate of TRAMP mice fed genistein at 250 ppm in the diet\(^{(180)}\). Genistein (1–10 \(\mu M\)) also increased ERK1/2 activity in non-tumorigenic epithelial RWPE-1 prostate cells via an estrogen-dependent mechanism, while supra-physiological concentrations (\(>25 \mu M\)) decreased ERK1/2 signalling\(^{(14,158,177,204–206)}\). Downstream targets c-Jun and c-fos, members of the AP-1 complex which is located in promoter regions of several genes discussed in this paragraph, were demonstrated to be upregulated by genistein in breast cancer models in vivo and in vitro. While the dose inducing this effect was 0.1 mg/kg bw in mice, it was much higher (74 \(\mu M\)) in ER positive and negative breast cell lines\(^{(154)}\).

Isoflavones such as genistein were also reported to have a possible effect on DNA repair. The tumour suppressor genes BRCA1 and BRCA2 are high penetrance genes associated with an increased risk of estrogen-responsive hereditary cancers such as breast and ovarian cancer and their mutations are also linked to an increased risk of developing androgen-dependent pathologies such as prostate cancer\(^{(206,207)}\). The corresponding proteins are involved in crucial cellular processes like cell proliferation, DNA repair and control of gene expression, notably through the regulation of ER- and AR-dependent transcriptional activities\(^{(207,208)}\). Physiological doses of genistein (0.5–2.5 \(\mu M\)) upregulated BRCA1 and BRCA2 protein expression in MCF-7 and T47D breast and LNCaP and DU-145 prostate cells in vitro\(^{(209)}\). An in vivo study reported that administration of 1.25–3.3 \(\mu g\) genistein/g bw during prepuberty resulted in a long-lasting increase in BRCA1 mRNA levels in mammary glands of 3 and 8-week old female Sprague–Dawley rats\(^{(51)}\). Furthermore, BRCA2 mRNA expression was upregulated in mammary glands of ovariecotomised Wistar rats fed an isoflavone-formulated diet (soylife) providing 8 \(\mu g\) isoflavones/g bw for 90 days\(^{(210)}\).

Isoflavones are thus candidate regulators of BRCA1 expression, possibly through their interaction with hormone receptors.

The modulation of antioxidant and xenobiotic enzyme systems towards reduction of oxidative stress and carcinogen detoxification is another key player in cancer prevention. Although the direct antioxidant capacity of soy isoflavones by scavenging free radicals or preventing LDL oxidation was mostly observed at high doses in vitro\(^{(211–213)}\), evidence exists that isoflavones may induce antioxidant enzyme systems as shown in vitro in breast and prostate cells at concentrations observed in plasma, or in vivo after soy consumption. Genistein at 10 \(\mu M\) induced gene and protein expression of several antioxidant enzymes such as glutathione peroxidase (GPX), glutathione reductase (GSR), microsomal glutathione S-transferase 1 (mGST-1) and metallothionein 1X (MT-1X) in LAPC-4 prostate cancer cells\(^{(214)}\). A lower concentration (0.5 \(\mu M\)) of genistein also induced the transcription of Mn-SOD gene in MCF-7 cells\(^{(203)}\). Furthermore, isoflavone supplementation of 138 mg/d for 24 days increased Cu/Zn-SOD activities in erythrocytes of breast cancer survivors\(^{(215)}\). Several xenobiotic enzymes involved in the activation of pro-carcinogens or in the detoxication of the carcinogens were influenced by isoflavones as shown in non-tumorigenic and tumorigenic breast cells using low doses of isoflavones, as well as in rat and human mammary glands. Levels of toxicifying Phase I enzymes, such as cytochrome P450 (CYP) 1A1, 1A2 and 1B1 were decreased by 430 ppm isoflavones in the diet of female Sprague–Dawley rats\(^{(210)}\), by 0.7–15 \(\mu M\) genistein in MCF-7 cells\(^{(217)}\) and in premenopausal women after supplementation with 400 mg daidzein/d\(^{(218)}\). Detoxifying Phase II enzymes such as GSTP1 and quinone reductase (QR) were upregulated at 1–10 \(\mu M\) genistein in non-tumorigenic MCF-10A and tumourigenic MCF-7 and MDA-MB-231 breast cells\(^{(219,220)}\).

The influence of isoflavones in the metabolism of vitamin D has also been explored. However, the potentially protective effect of genistein through an increase in the synthesis of the antiproliferative metabolite 1,25-dihydroxy-vitamin D3 in breast and prostate cancer cells was only observed at high non-physiological concentrations\(^{(221,222)}\). Similarly, inhibition of topoisomerase II and modulation of telomerases were only shown in cell culture models exposed to supra-physiological concentrations of genistein, thus, are unlikely to play a role in the prevention of breast and prostate cancer\(^{(196,223,224)}\).

To summarise the mechanisms of action of isoflavones discussed herein for breast cancer it is suggested that the inhibition of cell cycle and induction of apoptosis, promotion of differentiation, as well as the inhibition of angiogenesis, invasion and metastasis are probable modes of action of isoflavones as they were observed at physiologically relevant doses in vivo as well as in vitro. Modulation of the ER pathways and the metabolism of steroid hormones are certainly involved, whereas the regulation of cell signalling pathways
Isoflavones and the prevention of breast and prostate cancer

ES97

gave inconsistent results. Some supportive evidence exists for the modulation of EGF, IGF-1, MAPK, Akt and PPARγ pathways, whereas the effects of isoflavones on NF-κB signalling need to be further explored. Furthermore, the stimulation of antioxidant enzyme systems, the modulation of the xenobiotic metabolism towards enhanced detoxification and boosting of DNA repair have also been demonstrated at physiological isoflavone concentrations in breast cells.

The most likely mechanisms of action of isoflavones involved in the prevention of prostate cancer include interaction with AR and ER pathways and improvement of DNA repair. While inhibition of cell cycle was reported to occur only at supra-physiological concentrations, inhibition of angiogenesis, invasion and metastasis may occur at lower doses compatible with dietary exposure. Further studies are needed to establish the effects of isoflavones on the metabolism of steroids, on the modulation of antioxidant enzyme systems and xenobiotic metabolism, as well as on EGF, IGF-1, PPARγ and Akt signalling pathways in prostate cells.

Modulation of vitamin D metabolism, effect on telomeres, direct scavenging of free radicals or inhibition of topoisomerases II were only described at isoflavone concentrations far exceeding the physiological serum levels, raising doubts on their role in the prevention of breast and prostate cancer.

Effects on gene expression and microarray analyses

Targeted approaches focusing on the activity of one compound on one particular gene or protein, as described in the previous section, have been widely used in pharmacology, generally with success; however, they do not seem to be sufficient to elucidate the mechanisms of action of isoflavones at dietary levels of exposure. Diet is a very complex system, consisting of a huge number of possible combinations of diverse nutrients and micronutrients. Each constituent may have an impact on several metabolic or signalling pathways, and dietary constituents can exert opposite, additional or synergistic effects.

Furthermore, there is abundant evidence of cross-talks between ERs and AR, EGF and IGF-1 signalling in breast and prostate cancer cells. AR and ERs can be activated by growth factors and compounds that modulate the MAPK cascade, or the phosphatidylinositol-3 kinase (PI3K)/Akt-mediated cell survival pathway. In prostate cancers that have evolved to androgen independence, growth factor receptors may activate androgen receptors in the absence of androgens. Bidirectional interactions exist. For example, the IGF-1R is directly activated by liganded ER, IGF signalling transcriptionally activates the ER, and IGF-1 and estrogens have synergistic effects on cell cycle signalling cascades and proliferation. Signal cross-talk also exists bidirectionally between PPARγ and ER in breast cancer cells. ERs and PPARγ pathways have an opposite effect on the regulation of the PI3K/Akt transduction cascade. A variety of studies have shown that activated ER and PPAR can inhibit the activity of the transcription factor NF-κB, which plays a key role in the control of genes involved in inflammation, cell proliferation and apoptosis. A cross-talk between NF-κB and Akt signalling pathways has been suggested in genistein-treated MDA-MB-231 breast cancer cells. Moreover, NF-κB activation was reported to inhibit the tumour suppressor PTEN expression, which functions as a negative regulator of the PI3K/Akt pathway, whereas activated PPARγ has been shown to upregulate PTEN transcription. These non-exhaustive examples of established cross-talks potentially involved in breast and prostate carcinogenesis show how complex the interactions between the various signalling pathways are.

Inter-organ relationships must also be considered. For example, the liver and the immune system certainly play a role in the aetiology of breast and prostate cancer. Therefore it appears evident that targeted approaches are not sufficient to study the effects of dietary compounds on the prevention of these diseases. High-throughput methods such as transcriptomics, proteomics and metabolomics have been recently introduced in the nutrition field.

Large scale gene expression profiling through the use of DNA microarrays consists in measuring simultaneously the expression of hundreds or thousands of genes in a given sample using a single hybridization step. The comparison of these transcriptomic signatures obtained in different experimental conditions offers the possibility to reveal gene networks and signal transduction pathways modulated by a dietary intervention. It allows venturing new hypotheses about mechanisms of action. This is a valuable progress since targeted approaches may favour the systematic focus on a few genes or proteins that are already known to be implicated but may not be the only or the most important actors.

Similarities and differences between phytoestrogen and estrogen activities have been investigated in this way, by comparison of transcriptomic signatures induced by isoflavones or estradiol exposure in MCF-7 cells or mouse estrogen-responsive tissues. Results have been conflicting with some studies describing very similar transcriptional responses and others reporting only limited overlapping between expression patterns elicited by estradiol and genistein. It was suggested that differences in transcriptional signatures may arise from concentration-dependent variations in the magnitude and kinetics of gene expression rather than from modulation of distinct pathways. The question of the dose therefore appears crucial. The number of genes whose expression is affected by estradiol increased with its concentration in MCF-7 cells and in the uterus of immature female rats. In human endometrial cancer cells, a strong dose-dependency in the number of genes regulated by genistein was also observed: 2, 95 and 508 genes were affected by genistein exposure at 0.5, 5 and 50 μM respectively. Shioda et al. obtained a gene expression profile after exposure of MCF-7 cells to 30 pm estradiol undistinguishable from that obtained with exposure to 3 μM genistein, but clearly different to the profile obtained after exposure to 10 μM genistein. Gene expression profiling thus allows comparing different estrogenic compounds but the results must be interpreted with caution due to this strong dependence on the dose. The few studies that used physiological doses of genistein and estradiol rather showed similar gene expression profiles with genistein and estradiol but more studies are clearly needed.

Microarrays may also be useful to study molecular mechanisms. They have been used to identify novel androgen-responsive genes or genes induced in common by peptide growth factors and androgen in human prostate epithelial cells. Microarrays have been used to study isoflavone mechanisms of action and build up new hypotheses of research. Only few studies, described below, have applied this technique on cell
models exposed to physiologically relevant conditions, e.g. with exposures consistent with isoflavone concentrations achievable in humans.

Global gene expression profiles analysed after a 24-h exposure of MCF-7 and T47D cells to 1 μM genistein showed large similarities with those obtained after exposure to 30 pm estradiol(242). Using a threshold fold-change of 3, the authors found 97 upregulated genes, and 36 downregulated genes in genistein-treated MCF-7 cells, mainly involved in cell cycle, apoptosis, DNA metabolism, growth stimulation, cell adhesion, as well as xenobiotic metabolism and transport systems. Fewer genes were regulated by genistein in T47D cells but the same functions were affected. Shioda et al. showed using Affymetrix pangenomic microarrays that exposure of MCF-7 cells to 3 μM genistein for 48 h resulted in the upregulation of genes mainly involved in cell cycle progression, purine and pyrimidine synthesis, as well as steroid biosynthesis(241).

Few studies have been carried out in vivo. Thomsen et al. investigated the effects of neonatal or prepubertal exposure to 270 ppm genistein in the diet at the transcriptional and histological levels by using cDNA microarrays and immunohistochemical analysis of selected regulated genes(243). Changes in gene expression were clearly related to an increase in the number of epithelial mammary cells expressing the genes rather than to a specific regulation within the cells. This finding supported the hypothesis of a role of genistein in promoting earlier differentiation of the mammary gland.

In the mammary gland of male rats life-long exposed to genistein through maternal supplementation then directly in the diet after weaning until postnatal day 90, 90 genes were up or downregulated by at least 2-fold. The following genes were upregulated: growth factors (FGF 5), receptors (IGF-2R, TGFβ-2 type receptor, acetylcholine receptor β, inositol 1,4,5-trisphosphate receptor type 1), kinases (adenylate kinase 1 and 3, pyruvate dehydrogenase kinase). Genistein downregulated expression of various enzymes involved in lipid metabolism (phospholipase C β3, phospholipase C 54, phospholipase Cy1, pancreatic lipase, hepatic lipase), small molecule receptors (glutamate receptor, prostaglandin F 2 receptor) and solute transporters (solute carrier family 2, 10, 13, 18, voltage-gated sodium channel) as well as organic cation transporter-like 1 and hydroxysteroid dehydrogenase 11β type 1(245). The effects on energy metabolism and transport systems constitute new putative mechanisms of action of isoflavones that will have to be investigated further.

In the context of prostate cancer, a series of elegant studies using pangenomic microarrays to investigate the chemopreventive mechanisms of action of isoflavones have been published(246–248). The authors exposed the human androgen-responsive prostate cancer cells LNCaP to 1, 5 and 25 μM genistein, daidzein or equol for 48 h, and showed that the number of regulated genes increased markedly with the concentration to which cells were exposed: 521, 484 and 101 genes were regulated by 25 μM equol, genistein and daidzein respectively whereas only 14, 3 and 29 genes were regulated by the same compounds at 1 μM. The nature of the regulated pathways also depended on the concentration: 1 μM genistein affected androgen-regulated genes and IGF-1 pathway, concentration of 5 μM affected cell cycle control genes and PPARα signalling, whereas genes related to DNA damage and stress response pathways were upregulated at a 25 μM concentration. Genistein, daidzein and equol induced similar effects on the androgen-responsive genes and IGF-1 pathways, but resulted in a different modulation of steroid/xenobiotic metabolism genes and cell cycle-related genes.

Targeted microarrays may also be useful and are often easier to interpret. Raschke et al. (214) firstly showed with the comet assay that genistein (1–30 μM) protected prostate LAPC-4 cells from hydrogen peroxide-induced DNA damage. Using a targeted cDNA macroarray containing 192 genes involved in biotransformation or stress response, the authors showed that genistein modulated the expression of 3 of these genes at 1 μM and 19 genes at 10 μM. Real-time PCR confirmed the induction of these genes encoding products with antioxidant activities, namely GSR, mGST-1 and MT-1X possibly contributing to prevent DNA damage.

Seven other studies reported the use of the microarray technique on prostate cancer cells exposed to very high concentrations of isoflavones (45–100 μM)(155,200,249–252). Although these studies may be useful to investigate the putative therapeutic effects of pharmacological doses of isoflavones, they are not useful to examine the mechanisms of action involved in the preventive effects of nutritional doses of isoflavones and thus are beyond the scope of this review. No studies are available to date on gene expression profiles induced by isoflavones in animal prostate.

Although the microarray technology has greatly progressed in the last few years, there are still some limitations. One important issue is the study design and the choice of the appropriate model. Due to high cost of the microarray approach, frequently only one dose or time point is tested, and this does not allow understanding properly the dynamics of changes in gene expression and cell signalling. Another debate is related to the use of cell lines or freshly isolated tissues. Results obtained with cell lines cannot be easily extrapolated to humans due to differences in their genome and to their different environment. On the other hand, isolated tissues are complex and made of a variety of cell types, and reproducibility is hampered by inter-individual differences. However, the heterogeneity of tissue samples and the interactions of the different cell types reflect more precisely the biological gene expression profile. Hence, in order to obtain statistically significant data, a rather large set of samples is required resulting in costly experiments.

Data analysis and interpretation of the large data sets using public databases such as gene network, gene pathway and genome ontology databases are critical issues. The defined cut-off level for differentially expressed genes, based on the fold changes, is also questioned. To date, relatively high fold change thresholds (above 2-fold) have been chosen. However, in microarray analyses using nutritional doses of micro-nutrients only low fold changes are frequently observed. Low fold changes may actually have a physiological impact, since a small regulation of several genes in one pathway might give an additive effect on the outcome. One must bear in mind that the microarray technology is a precious tool to build up new hypotheses of research while considering the complexity of metabolic and signalling pathways however classical approaches such as quantitative measurement of RNA levels (northern blot, RT-PCR, or in situ hybridization) or protein levels (immunohistochemistry or western blot), as well as biochemical analyses are still necessary for the final validation.
of mechanistic hypotheses and the ultimate establishment of a causal relationship between altered gene expression and a given disease or dietary intervention.

Proteomics

Rowell et al. used a proteomic approach to investigate the effects of prepubertal exposure to genistein before chemically induced mammary carcinogenesis and found the GTP cyclohydrolase1 protein (GTP-CH1) significantly upregulated in mammary glands. The authors used extensive literature and web searching to find information about related pathways that might explain how this particular protein might play a role in mammary cancer chemoprevention. They speculated that downstream signalling from GTP-CH1 would upregulate tyrosine hydroxylase, resulting in dynamic upregulation of catecholamines. This in turn, would decrease vascular endothelial growth factor receptor 2 (VEGFR2) levels, resulting in decreased ability to promote angiogenesis. Immunoblot and immunohistochemistry analyses confirmed that the proteins of interest (GTP-CH1, tyrosine hydroxylase, and VEGFR2) were modulated in their expression in the lining of mammary epithelial cells of 50-day-old rats. This first study demonstrated the usefulness of proteomics for the discovery of novel pathways that may be involved in cancer prevention by isoflavones.

Metabolomics

Few metabolomics studies have still been published in the field of nutrition. However, two NMR-based studies have been carried out to investigate the effects of soy isoflavone consumption. The 1H NMR spectral profiles of plasma and urine from premenopausal women before and following soy or miso consumption revealed significant changes in metabolites associated with energy metabolism. The results suggested an inhibitory effect of isoflavones on glycolysis, resulting in a general shift in energy metabolism from carbohydrate metabolism to lipid metabolism.

Metabolomics is theoretically a better tool to characterize metabolic phenotypes and the effects of dietary interventions on these phenotypes than transcriptomics or proteomics, since changes in gene or protein expression do not necessarily lead to changes in metabolite concentrations. However many technical hurdles still hamper progresses in this approach, as discussed in other reviews. The present limit of the use of NMR-based metabolomics is the low sensitivity of the technique. The alternative is the use of mass spectrometry-based metabolomics but problems of standardization and robustness still have to be addressed. Furthermore, more efficient methods must still be developed to improve the automated identification of markers.

Epigenetic regulation

DNA methylation, usually occurring at promoter CpG islands, as well as acetylation and methylation of critical lysine residues on histones are key epigenetic mechanisms for the silencing of many genes involved in carcinogenesis, including tumour suppressor genes (such as BRCA1, p53, and caveolin-1), genes encoding hormone receptors, DNA repair enzymes, mediators of the apoptosis pathway, and detoxification enzymes. Various techniques, such as methylation-specific oligonucleotide microarrays (MSO), methylation target array (MTA), cytosine extension assay and pyrosequencing now allow assessing global and gene specific DNA methylation. For example, using methylation-specific oligonucleotide microarrays, Yu et al., demonstrated that DNA methylation target array (MTA), cytosine extension assay and pyrosequencing now allow assessing global and gene specific DNA methylation. For example, using methylation-specific oligonucleotide microarrays, Yu et al., demonstrated that 25 genes among the 105 studied were methylated in prostate cancer cell lines but not in normal primary prostate tissue samples. A few available reports indicate that genistein could regulate cancer-related gene transcription by modulating epigenetic events such as DNA methylation and/or histone acetylation, either directly or through an estrogen receptor-dependent process. Day et al. reported that the consumption of a genistein diet (300 ppm) by adult male mice was associated to a partial change in the global DNA methylation pattern in the mouse prostate. In LNCaP and PC3 cells, genistein reversed DNA hypermethylation and reactivated the methylation-silenced genes retinoic acid receptor β (RARB), p16, and O-methylguanine methyltransferase (MGMT), but only when used at a high concentration (20 μM). However, genistein at 5 μM enhanced the activity of the demethylating agent 5-aza-2-deoxycytidine and the histone acetylation drug trichostatin in the reactivation of these genes. Moreover, genistein, equal to or a lesser extent daidzein were shown to stimulate in vitro histone acetylation mediated by ERα and ERβ and their coactivators, an effect likely to be associated to stimulated transcription. Epigenetic effects of isoflavones thus undoubtedly constitute a novel promising axis of research.

In conclusion, although many isoflavone effects have already been established using classical targeted approaches, the exact mechanisms of action have not yet been established. Classical molecular approaches have been used, often in vitro models, to explore specific hypotheses. The results often still need to be validated in vivo in nutritional conditions. The more recent studies using transcriptomic, proteomic and metabolomic high-throughput techniques obviously demonstrated their potential to describe the complexity of the biological effects of isoflavones and provide us with more comprehensive insights into how isoflavones may contribute to prevent breast and prostate cancers. New hypotheses on the molecular and cellular mechanisms of action of isoflavones have already been opened and there is no doubt that others will rapidly emerge from the increasing use of nutrigenomics approaches in the near future. Major discoveries regarding their mechanisms of action and their variability according to individuals, dose or timing of exposure still seem conceivable.

Acknowledgements

The publication of this paper was made possible by the financial support of the European Co-operation in the field of Scientific and Technical (COST) Research Action 926 “Impact of new technologies on the health benefits and safety of bioactive plant compounds” (2004–2008). The authors had no conflicts of interest to disclose.
References


77. Sánchez-Camacho C. Steiner et al.


Isoflavones and the prevention of breast and prostate cancer


Isoflavones and the prevention of breast and prostate cancer

ES105


Isoflavones and the prevention of breast and prostate cancer


